News

Meta’s Muse is gaining traction despite Amazon’s pushback, keeping analysts optimistic about the company’s AI-driven growth.

Nvidia CEO Jensen Huang was wrong when he predicted Marvell would be the next trillion-dollar chip company.

SpaceX has three enormous opportunities in Starlink, launch services, and AI.

Key TakeawaysHeidi O’Neill took over as Lululemon’s CEO on September 8, 2026, after an 18% single-day stock drop to an eight-year low, but its margin data shows gross margin had already slid from 60. 42% in February 2025 to 54.

Cardano's long slide downward will likely continue over the next three years.

Stock futures were little changed Wednesday after the tech-focused Nasdaq Composite registered its second consecutive record-high close, as oil prices and Treasury yields wavered.

Bitcoin sits just a whisker away from erasing its 2026 losses, but a rising rate environment, a stalled Senate bill, and fading short-squeeze fuel threaten to pull it back before December 31 arrives.

The mood on Wall Street remained calm on Tuesday, even after President Donald Trump threatened to "annihilate" Iran at a United Nations meeting. The Cboe Volatility Index, or VIX, held steady at just over 14 in early trading.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 38.9% gain over the past six months, beating the S&P 500 by 20.9 percentage points.

Monster Beverage has already built one of the world's strongest energy-drink brands. But the bigger opportunity may be what happens next.

Sandisk’s stock is down close to 20% over the past three months after its stellar run over the past year.

Here's why investors should respond with more selectivity, not panic.

EUFN delivered 26.3% returns over one year but charges 0.49% annually. FNCL costs just 0.08% with broader U.S. exposure across almost 400 holdings.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 38.9% over the past six months, topping the S&P 500 by 20.9 percentage points.

Style Box ETF report for VB

Sector ETF report for IYT

Sector ETF report for EUFN

Style Box ETF report for IJJ

You can take these companies' dividends straight to the bank.

The AI trade has stalled as spending on tokens and chips falters, Fidelity's head of macro, Jurrien Timmer, wrote on X. Investing in AI companies "has been dead money for more than three months," Timmer wrote. Token expenditures—or the spending on AI computation—as well as the leasing of semiconductor chips are both flat or lower since June, according to Fidelity data.

Shares of chip and memory companies slip as investors lock in some profit, but AI server makers are having a better time of it.

The OECD says the global economy has absorbed the Iran war better than feared, but flags energy supply as a key risk. That keeps reliable, low carbon power in sharp focus. Investors who wait for full clarity often watch opportunities pass by. This article walks through three nuclear energy stocks from our screener that offer different ways to gain exposure to this long term power theme. The three nuclear energy stocks below are only a starting sample, and the full screen surfaced 34 more...

In recent trading, optimism around agentic artificial intelligence and Meta Platforms' Muse application boosted expectations for heightened CPU and memory demand, lifting sentiment toward Seagate Technology Holdings. The shift toward more autonomous AI workloads is drawing attention to Seagate’s role in supplying the mass-capacity storage infrastructure needed to support these data-intensive applications. We’ll now examine how rising enthusiasm for agentic AI demand, especially around...

Rigetti Computing has seen its share price move around sharply in recent years, which naturally puts a spotlight on whether the current US$16.52 level lines up with the book value on its balance sheet. With that kind of volatility in the rear-view mirror, the question now is how much of the recent share price story is actually supported by the company’s net assets per share. Over the past 3 years the stock has delivered a very large gain of roughly 11x. That raises the question of how that...

Alphabet's (GOOG) (GOOGL) Google is facing fresh proposals from the UK's Competition and Markets Aut

Block (NYSE:XYZ) is expanding its Square partnership with Ideal Nutrition as the meal prep brand rolls out nationally across the US. Ideal Nutrition is adopting Square tools across in-store POS, online ordering, loyalty programs, and franchise management for its expansion. The rollout includes AI-driven demand forecasting and cross-platform integrations that link Ideal Nutrition’s retail, logistics, and customer data in one system. Ideal Nutrition’s Square-powered national expansion and...

Cisco Systems (NasdaqGS:CSCO) announced a collaboration with quantum technology firm Infleqtion to advance distributed quantum networking architectures. The partners plan to work on quantum memory to optical transduction and networked quantum devices for long distance connectivity. Cisco highlighted a prototype Universal Quantum Switch as part of its push to connect, operate, and scale quantum systems. The Infleqtion partnership and Universal Quantum Switch prototype only capture one part of...

Micron is enjoying a generational demand wave.

Royal Caribbean Group (NYSE:RCL) has agreed to acquire a 50% stake in Sandals and Beaches Resorts for approximately $3 billion, expanding the cruise operator’s business into the all-inclusive resort market. The companies said Wednesday that the investment will create a joint venture combining the Caribbean resort portfolio of Sandals and Beaches with Royal Caribbean’s cruise, private destination and vacation operations.

Novo Nordisk (NYSE:NVO) would be open to considering a direct listing of its shares on the New York Stock Exchange, Chief Executive Mike Doustdar told the Financial Times in an interview published Wednesday. Doustdar said he could see advantages to such a move when asked about the possibility, although he clarified that the Danish pharmaceutical company is not currently exploring a change to its U.